Regencell Bioscience Holdings Limited (NASDAQ:RGC) Short Interest Down 16.3% in January

Regencell Bioscience Holdings Limited (NASDAQ:RGC) saw a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 773,634 shares, a drop of 16.3% from the January 15th total of 924,708 shares. Based on an average trading volume of 542,921 shares, the short-interest ratio is currently 1.4 days. Currently, 0.2% of the shares of the company are short sold. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 542,921 shares, the short-interest ratio is currently 1.4 days.

Regencell Bioscience Stock Up 7.6%

RGC stock traded up $2.20 during midday trading on Monday, hitting $31.22. The company’s stock had a trading volume of 375,183 shares, compared to its average volume of 341,173. Regencell Bioscience has a 1 year low of $0.09 and a 1 year high of $83.60. The stock’s 50-day moving average price is $26.60 and its 200 day moving average price is $18.72.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Regencell Bioscience in the 2nd quarter valued at approximately $1,701,000. BNP Paribas Financial Markets purchased a new position in Regencell Bioscience during the second quarter valued at $768,000. XTX Topco Ltd purchased a new position in Regencell Bioscience in the third quarter worth about $598,000. Finally, Hudson Bay Capital Management LP bought a new stake in Regencell Bioscience in the 4th quarter worth approximately $275,000. 0.13% of the stock is currently owned by institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.